Eximo Medical announces completion of its series A round and plans for first in human trial

293

Eximo Medical has completed its series A funding round of US$1.6 million. Accelmed, a medical device Investment Fund, led the round, with the participation of the Alfred Mann Institute at the Technion (AMIT), the Technion R&D Foundation Ltd and a private investor.

Eximo has developed a patented hybrid catheter, Cathi, which is connected to a pulsed laser system that operates at 355nm UV. The catheter’s tip combines laser ablation capabilities with a mechanical blunt blade. This combination will potentially improve accuracy, and enable superior precision when passing through a vessel blockage, regardless of the type of lesion or size of the vessel.

According to Eximo, the Cathi technology has the potential to optimise safety and performance expected to reduce the risk of vessel perforation. The performance of the system and its catheters in treating peripheral arterial disease will soon be tested in human studies in Europe and Israel during Q4, this year.

Eximo’s first set of catheters will offer a range of unique solutions for different blockage pathologies during atherectomy procedures in patients with peripheral arterial disease.

Irit Yaniv, chairperson of Eximo, said, “We have been engaged in the development of our Cathi technology for several years and are excited to have reached the stage to take its main application—the treatment of peripheral arterial disease patients—through its first-in-human clinical trials later in the year. We have every faith in the relevance of our laser system and hybrid catheters which we believe have several advantages over existing solutions in the market.”

Eximo’s product pipeline includes solutions for lead extraction—the removal of defunct, malfunctioning or infected pacemaker or fibrillator leads and, at a later stage, catheters for interventional gastrointestinal procedures.

Eximo Medical Ltd, founded in 2012, is an Israeli company dedicated to developing safe and efficient transluminal solutions for interventional vascular and gastrointestinal procedures. The company’s Cathi catheters are based on innovative technology comprising a proprietary hybrid laser and “blunt” blade components and a compact laser system with a tiny footprint.

(Visited 11 times, 1 visits today)